Roche的新药物组合大大改善了先进的乳腺癌患者在CDK4/6治疗后的生存能力,根据2025年ESMO数据。 Roche's new drug combo significantly improved survival for advanced breast cancer patients post-CDK4/6 therapy, per 2025 ESMO data.

Roche将在2025年ESMO大会上提供新数据,表明在CDK4/6抑制剂治疗后,高乳癌患者在达到关键试验终点后无进展存活率显著提高。 Roche will present new data at the 2025 ESMO Congress showing that giredestrant plus everolimus significantly improved progression-free survival in advanced breast cancer patients after CDK4/6 inhibitor treatment, meeting key trial endpoints. Tecentriq Adjuvant Tecentriq改善了肌肉侵入性膀胱癌患者的存活率,可检测到循环肿瘤DNA,支持CtDNA制导治疗。 Adjuvant Tecentriq improved survival in muscle-invasive bladder cancer patients with detectable circulating tumor DNA, supporting ctDNA-guided therapy. 最终总体生存数据确认,Alecensa是ALK阳性肺癌的标准一线治疗,对早期疾病有持续的好处。 Final overall survival data confirmed Alecensa as a standard first-line treatment for ALK-positive lung cancer, with sustained benefits in early-stage disease. 其他研究还在研究早期乳腺癌的治疗方法. Additional studies explore giredestrant and combination therapies in early breast cancer.